Revenue for fiscal 2025 reached KRW 31.1 billion, up about 24% from 2024, according to JobKorea's compiled financial data. Operating profit rose from KRW 0.2 billion in 2024 to KRW 1.3 billion in 2025, showing improvement at the operating level.
Non-operating costs grew to about KRW 6.1 billion, and the company posted a net loss of KRW 2.2 billion after a net profit of similar size in 2024. On a standalone basis compiled by FnGuide from DART filings, 2024 revenue was KRW 25.1 billion, operating profit KRW 0.2 billion, and net profit KRW 2.2 billion.
Standalone equity moved from about KRW 6.0 billion at end-2024 to about negative KRW 1.7 billion at end-2025, a state of full capital impairment. Paid-in capital declined from about KRW 11.2 billion to about KRW 8.7 billion over the same period.
The fiscal 2025 annual report was filed on March 23, 2026, with a corrected filing on March 30, 2026. At the annual general meeting on March 31, 2026, shareholders approved the fiscal 2025 financial statements and reappointed the external auditor.
According to Korea Exchange data for December-year-end KONEX companies, biotech sector revenue rose 9.0% in 2025, while losses persisted. As of 2:10 a.m. KST on November 11, 2026, the share price was KRW 400, unchanged from the prior session, with trading value of KRW 58,200.